Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice

Cell

Volumn 158, Issue 5, 2014, Pages 989-999

  Halper Stromberg, Ariel ^a   Lu, Ching Lan ^a,b   Klein, Florian ^a   Horwitz, Joshua A ^a   Bournazos, Stylianos ^a   Nogueira, Lilian ^a   Eisenreich, Thomas R ^a   Liu, Cassie ^a   Gazumyan, Anna ^a   Schaefer, Uwe ^a   Furze, Rebecca C ^c   Seaman, Michael S ^d   Prinjha, Rab ^c   Tarakhovsky, Alexander ^a   Ravetch, Jeffrey V ^a   Nussenzweig, Michel C ^a,e  

^a ROCKEFELLER UNIVERSITY   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 (3,5 DIMETHYL 4 ISOXAZOLYL) 1,3 DIHYDRO 8 METHOXY 1 [1 (2 PYRIDINYL)ETHYL] 2H IMIDAZO[4,5 C]QUINOLIN 2 ONE; BROADLY NEUTRALIZING ANTIBODY; EMTRICITABINE; FC RECEPTOR; NEUTRALIZING ANTIBODY; RALTEGRAVIR; TENOFOVIR; UNCLASSIFIED DRUG; VORINOSTAT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FUSED HETEROCYCLIC RINGS; HYDROXAMIC ACID; IMMUNOGLOBULIN FC FRAGMENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOTHERAPY; MOUSE; NONHUMAN; POST EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; REBOUND; RESERVOIR; VIREMIA; VIRUS LOAD; VIRUS TRANSCRIPTION; ANIMAL; DRUG EFFECTS; GENETIC TRANSCRIPTION; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; PHYSIOLOGY; VIROLOGY; VIRUS LATENCY;

HUMAN IMMUNODEFICIENCY VIRUS 1; MUS;

ANIMALS; ANTI-HIV AGENTS; ANTIBODIES, NEUTRALIZING; CD4-POSITIVE T-LYMPHOCYTES; CTLA-4 ANTIGEN; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HIV INFECTIONS; HIV-1; HUMANS; HYDROXAMIC ACIDS; IMMUNOGLOBULIN FC FRAGMENTS; MICE; RECEPTORS, FC; TRANSCRIPTION, GENETIC; VIRUS LATENCY;

EID: 84907379431     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2014.07.043     Document Type: Article

References (70)

1. I.A. Abela, L. Berlinger, M. Schanz, L. Reynell, H.F. Günthard, P. Rusert, and A. Trkola Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies PLoS Pathog. 8 2012 e1002634
2. L.M. Agosto, P. Zhong, J. Munro, and W. Mothes Highly active antiretroviral therapies are effective against HIV-1 cell-to-cell transmission PLoS Pathog. 10 2014 e1003982
3. Y. Aida, and M.J. Pabst Removal of endotoxin from protein solutions by phase separation using Triton X-114 J. Immunol. Methods 132 1990 191 195
4. M.L. Alegre, K.A. Frauwirth, and C.B. Thompson T-cell regulation by CD28 and CTLA-4 Nat. Rev. Immunol. 1 2001 220 228
5. N.M. Archin, A. Espeseth, D. Parker, M. Cheema, D. Hazuda, and D.M. Margolis Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid AIDS Res. Hum. Retroviruses 25 2009 207 212
6. N.M. Archin, K.S. Keedy, A. Espeseth, H. Dang, D.J. Hazuda, and D.M. Margolis Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors AIDS 23 2009 1799 1806
7. N.M. Archin, A.L. Liberty, A.D. Kashuba, S.K. Choudhary, J.D. Kuruc, A.M. Crooks, D.C. Parker, E.M. Anderson, M.F. Kearney, and M.C. Strain et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy Nature 487 2012 482 485
8. N.M. Archin, R. Bateson, M. Tripathy, A.M. Crooks, K.H. Yang, N.P. Dahl, M.F. Kearney, E.M. Anderson, J.M. Coffin, and M.C. Strain et al. HIV-1 expression within resting CD4 T cells after multiple doses of Vorinostat J. Infect. Dis. 2014 10.1093/infdis/jiu155 Published online April 24, 2014
9. D.H. Barouch, J.B. Whitney, B. Moldt, F. Klein, T.Y. Oliveira, J. Liu, K.E. Stephenson, H.W. Chang, K. Shekhar, and S. Gupta et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys Nature 503 2013 224 228
10. D. Boehm, V. Calvanese, R.D. Dar, S. Xing, S. Schroeder, L. Martins, K. Aull, P.-C. Li, V. Planelles, and J.E. Bradner et al. BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism Cell Cycle 12 2013 452 462
11. D. Boehm, V. Calvanese, R.D. Dar, S. Xing, S. Schroeder, L. Martins, K. Aull, P.C. Li, V. Planelles, and J.E. Bradner et al. BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism Cell Cycle 12 2013 452 462
12. M. Bonsignori, J. Pollara, M.A. Moody, M.D. Alpert, X. Chen, K.K. Hwang, P.B. Gilbert, Y. Huang, T.C. Gurley, and D.M. Kozink et al. Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family J. Virol. 86 2012 11521 11532
13. M.A. Brehm, M.V. Wiles, D.L. Greiner, and L.D. Shultz Generation of improved humanized mouse models for human infectious diseases J. Immunol. Methods 2014 10.1016/j.jim.2014.02.011 Published online March 4, 2014
14. M.I. Bukrinsky, T.L. Stanwick, M.P. Dempsey, and M. Stevenson Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection Science 254 1991 423 427
15. C.K. Bullen, G.M. Laird, C.M. Durand, J.D. Siliciano, and R.F. Siliciano New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo Nat. Med. 20 2014 425 429
16. T.W. Chun, L. Stuyver, S.B. Mizell, L.A. Ehler, J.A. Mican, M. Baseler, A.L. Lloyd, M.A. Nowak, and A.S. Fauci Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy Proc. Natl. Acad. Sci. USA 94 1997 13193 13197
17. A.W. Chung, G. Isitman, M. Navis, M. Kramski, R.J. Center, S.J. Kent, and I. Stratov Immune escape from HIV-specific antibody-dependent cellular cytotoxicity (ADCC) pressure Proc. Natl. Acad. Sci. USA 108 2011 7505 7510
18. X. Contreras, M. Schweneker, C.S. Chen, J.M. McCune, S.G. Deeks, J. Martin, and B.M. Peterlin Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells J. Biol. Chem. 284 2009 6782 6789
19. R.D. Dar, N.N. Hosmane, M.R. Arkin, R.F. Siliciano, and L.S. Weinberger Screening for noise in gene expression identifies drug synergies Science 344 2014 1392 1396
20. R.T. Davey, N. Bhat, C. Yoder, T.W. Chun, J.A. Metcalf, R. Dewar, V. Natarajan, R.A. Lempicki, J.W. Adelsberger, and K.D. Miller et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression Proc. Natl. Acad. Sci. USA 96 1999 15109 15114
21. M.A. Dawson, R.K. Prinjha, A. Dittmann, G. Giotopoulos, M. Bantscheff, W.I. Chan, S.C. Robson, C.W. Chung, C. Hopf, and M.M. Savitski et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia Nature 478 2011 529 533
22. S.G. Deeks HIV: Shock and kill Nature 487 2012 439 440
23. P.W. Denton, R. Olesen, S.K. Choudhary, N.M. Archin, A. Wahl, M.D. Swanson, M. Chateau, T. Nochi, J.F. Krisko, and R.A. Spagnuolo et al. Generation of HIV latency in humanized BLT mice J. Virol. 86 2012 630 634
24. K.M. Dhodapkar, J.L. Kaufman, M. Ehlers, D.K. Banerjee, E. Bonvini, S. Koenig, R.M. Steinman, J.V. Ravetch, and M.V. Dhodapkar Selective blockade of inhibitory Fcgamma receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells Proc. Natl. Acad. Sci. USA 102 2005 2910 2915
25. J.B. Dinoso, S.Y. Kim, A.M. Wiegand, S.E. Palmer, S.J. Gange, L. Cranmer, A. O'Shea, M. Callender, A. Spivak, and T. Brennan et al. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy Proc. Natl. Acad. Sci. USA 106 2009 9403 9408
26. M. Dybul, B. Hidalgo, T.W. Chun, M. Belson, S.A. Migueles, J.S. Justement, B. Herpin, C. Perry, C.W. Hallahan, and R.T. Davey et al. Pilot study of the effects of intermittent interleukin-2 on human immunodeficiency virus (HIV)-specific immune responses in patients treated during recently acquired HIV infection J. Infect. Dis. 185 2002 61 68
27. S. Eriksson, E.H. Graf, V. Dahl, M.C. Strain, S.A. Yukl, E.S. Lysenko, R.J. Bosch, J. Lai, S. Chioma, and F. Emad et al. Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies PLoS Pathog. 9 2013 e1003174
28. F. Ferrantelli, K.A. Buckley, R.A. Rasmussen, A. Chalmers, T. Wang, P.L. Li, A.L. Williams, R. Hofmann-Lehmann, D.C. Montefiori, and L.A. Cavacini et al. Time dependence of protective post-exposure prophylaxis with human monoclonal antibodies against pathogenic SHIV challenge in newborn macaques Virology 358 2007 69 78
29. D. Finzi, M. Hermankova, T. Pierson, L.M. Carruth, C. Buck, R.E. Chaisson, T.C. Quinn, K. Chadwick, J. Margolick, and R. Brookmeyer et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy Science 278 1997 1295 1300
30. D.N. Forthal, G. Landucci, and E.S. Daar Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells J. Virol. 75 2001 6953 6961
31. D. Forthal, T.J. Hope, and G. Alter New paradigms for functional HIV-specific nonneutralizing antibodies Curr. Opin. HIV AIDS 8 2013 393 401
32. R.T. Gandhi, L. Zheng, R.J. Bosch, E.S. Chan, D.M. Margolis, S. Read, B. Kallungal, S. Palmer, K. Medvik, M.M. Lederman AIDS Clinical Trials Group A5244 team The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial PLoS Med. 7 2010 7
33. T. Hatziioannou, and D.T. Evans Animal models for HIV/AIDS research Nat. Rev. Microbiol. 10 2012 852 867
34. A.J. Hessell, L. Hangartner, M. Hunter, C.E. Havenith, F.J. Beurskens, J.M. Bakker, C.M. Lanigan, G. Landucci, D.N. Forthal, and P.W. Parren et al. Fc receptor but not complement binding is important in antibody protection against HIV Nature 449 2007 101 104
35. Y.C. Ho, L. Shan, N.N. Hosmane, J. Wang, S.B. Laskey, D.I. Rosenbloom, J. Lai, J.N. Blankson, J.D. Siliciano, and R.F. Siliciano Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure Cell 155 2013 540 551
36. H.M. Horton, M.J. Bernett, M. Peipp, E. Pong, S. Karki, S.Y. Chu, J.O. Richards, H. Chen, R. Repp, J.R. Desjarlais, and E.A. Zhukovsky Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies Blood 116 2010 3004 3012
37. J.A. Horwitz, A. Halper-Stromberg, H. Mouquet, A.D. Gitlin, A. Tretiakova, T.R. Eisenreich, M. Malbec, S. Gravemann, E. Billerbeck, and M. Dorner et al. HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice Proc. Natl. Acad. Sci. USA 110 2013 16538 16543
38. T. Igarashi, C. Brown, A. Azadegan, N. Haigwood, D. Dimitrov, M.A. Martin, and R. Shibata Human immunodeficiency virus type 1 neutralizing antibodies accelerate clearance of cell-free virions from blood plasma Nat. Med. 5 1999 211 216
39. S. Jost, and M. Altfeld Control of human viral infections by natural killer cells Annu. Rev. Immunol. 31 2013 163 194
40. F. Klein, A. Halper-Stromberg, J.A. Horwitz, H. Gruell, J.F. Scheid, S. Bournazos, H. Mouquet, L.A. Spatz, R. Diskin, and A. Abadir et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice Nature 492 2012 118 122
41. F. Klein, A. Halper-Stromberg, J.A. Horwitz, H. Gruell, J.F. Scheid, S. Bournazos, H. Mouquet, L.A. Spatz, R. Diskin, and A. Abadir et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice Nature 492 2012 118 122
42. T. Krejsgaard, K. Kopp, E. Ralfkiaer, A.E. Willumsgaard, K.W. Eriksen, T. Labuda, S. Rasmussen, A.M. Mathiesen, C. Geisler, and B. Lauenborg et al. A novel xenograft model of cutaneous T-cell lymphoma Exp. Dermatol. 19 2010 1096 1102
43. M.F. Krummel, and J.P. Allison CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation J. Exp. Med. 182 1995 459 465
44. E.D. Kwon, A.A. Hurwitz, B.A. Foster, C. Madias, A.L. Feldhaus, N.M. Greenberg, M.B. Burg, and J.P. Allison Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer Proc. Natl. Acad. Sci. USA 94 1997 8099 8103
45. A. Lafeuillade, C. Poggi, S. Chadapaud, G. Hittinger, M. Chouraqui, M. Pisapia, and E. Delbeke Pilot study of a combination of highly active antiretroviral therapy and cytokines to induce HIV-1 remission J. Acquir. Immune Defic. Syndr. 26 2001 44 55
46. R. Landovitz, and J. Curry Clinical practice. Postexposure Prophylaxis for HIV Infection N. Engl. J. Med. 361 2009 1768 1775
47. J.D. Lifson, J.L. Rossio, R. Arnaout, L. Li, T.L. Parks, D.K. Schneider, R.F. Kiser, V.J. Coalter, G. Walsh, and R.J. Imming et al. Containment of simian immunodeficiency virus infection: Cellular immune responses and protection from rechallenge following transient postinoculation antiretroviral treatment J. Virol. 74 2000 2584 2593
48. M. Malbec, F. Porrot, R. Rua, J. Horwitz, F. Klein, A. Halper-Stromberg, J.F. Scheid, C. Eden, H. Mouquet, M.C. Nussenzweig, and O. Schwartz Broadly neutralizing antibodies that inhibit HIV-1 cell to cell transmission J. Exp. Med. 210 2013 2813 2821
49. M.D. Marsden, M. Kovochich, N. Suree, S. Shimizu, R. Mehta, R. Cortado, G. Bristol, D.S. An, and J.A. Zack HIV latency in the humanized BLT mouse J. Virol. 86 2012 339 347
50. A.J. McMichael, P. Borrow, G.D. Tomaras, N. Goonetilleke, and B.F. Haynes The immune response during acute HIV-1 infection: clues for vaccine development Nat. Rev. Immunol. 10 2010 11 23
51. E. Nicodeme, K.L. Jeffrey, U. Schaefer, S. Beinke, S. Dewell, C.W. Chung, R. Chandwani, I. Marazzi, P. Wilson, and H. Coste et al. Suppression of inflammation by a synthetic histone mimic Nature 468 2010 1119 1123
52. F. Nimmerjahn, and J.V. Ravetch Fcgamma receptors as regulators of immune responses Nat. Rev. Immunol. 8 2008 34 47
53. M. Nischang, R. Sutmuller, G. Gers-Huber, A. Audigé, D. Li, M.-A. Rochat, S. Baenziger, U. Hofer, E. Schlaepfer, and S. Regenass et al. Humanized mice recapitulate key features of HIV-1 infection: A novel concept using long-acting anti-retroviral drugs for treating HIV-1 PloS One 7 2012 e38853
54. Y. Nishimura, T. Igarashi, N.L. Haigwood, R. Sadjadpour, O.K. Donau, C. Buckler, R.J. Plishka, A. Buckler-White, and M.A. Martin Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development Proc. Natl. Acad. Sci. USA 100 2003 15131 15136
55. J. Pietzsch, H. Gruell, S. Bournazos, B.M. Donovan, F. Klein, R. Diskin, M.S. Seaman, P.J. Bjorkman, J.V. Ravetch, A. Ploss, and M.C. Nussenzweig A mouse model for HIV-1 entry Proc. Natl. Acad. Sci. USA 109 2012 15859 15864
56. J.M. Prins, S. Jurriaans, R.M. van Praag, H. Blaak, R. van Rij, P.T. Schellekens, I.J. ten Berge, S.L. Yong, C.H. Fox, and M.T. Roos et al. Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy AIDS 13 1999 2405 2410
57. V. Quivy, E. Adam, Y. Collette, D. Demonte, A. Chariot, C. Vanhulle, B. Berkhout, R. Castellano, Y. de Launoit, and A. Burny et al. Synergistic activation of human immunodeficiency virus type 1 promoter activity by NF-kappaB and inhibitors of deacetylases: potential perspectives for the development of therapeutic strategies J. Virol. 76 2002 11091 11103
58. S. Reuse, M. Calao, K. Kabeya, A. Guiguen, J.S. Gatot, V. Quivy, C. Vanhulle, A. Lamine, D. Vaira, and D. Demonte et al. Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection PLoS ONE 4 2009 e6093
59. T. Schiffner, Q.J. Sattentau, and C.J. Duncan Cell-to-cell spread of HIV-1 and evasion of neutralizing antibodies Vaccine 31 2013 5789 5797
60. L. Shan, K. Deng, N.S. Shroff, C.M. Durand, S.A. Rabi, H.C. Yang, H. Zhang, J.B. Margolick, J.N. Blankson, and R.F. Siliciano Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation Immunity 36 2012 491 501
61. M. Shingai, Y. Nishimura, F. Klein, H. Mouquet, O.K. Donau, R. Plishka, A. Buckler-White, M. Seaman, M. Piatak Jr., and J.D. Lifson et al. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia Nature 503 2013 277 280
62. A. Sigal, J.T. Kim, A.B. Balazs, E. Dekel, A. Mayo, R. Milo, and D. Baltimore Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy Nature 477 2011 95 98
63. J.D. Siliciano, and R.F. Siliciano HIV-1 eradication strategies: design and assessment Curr. Opin. HIV AIDS 8 2013 318 325
64. J.D. Siliciano, J. Kajdas, D. Finzi, T.C. Quinn, K. Chadwick, J.B. Margolick, C. Kovacs, S.J. Gange, and R.F. Siliciano Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells Nat. Med. 9 2003 727 728
65. Y. Sun, M. Asmal, S. Lane, S.R. Permar, S.D. Schmidt, J.R. Mascola, and N.L. Letvin Antibody-dependent cell-mediated cytotoxicity in simian immunodeficiency virus-infected rhesus monkeys J. Virol. 85 2011 6906 6912
66. C.-C. Tsai, K. Follis, A. Sabo, T. Beck, R. Grant, N. Bischofberger, R. Benveniste, and R. Black Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl) adenine Science 270 1995 1197 1199
67. C.-C. Tsai, P. Emau, K. Follis, T. Beck, R. Benveniste, N. Bischofberger, J. Lifson, and W. Morton Effectiveness of postinoculation (R)-9-(2- phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIV infection depends critically on timing of initiation and duration of treatment J. Virol. 72 1998 4265 4273
68. A.P. West Jr., L. Scharf, J.F. Scheid, F. Klein, P.J. Bjorkman, and M.C. Nussenzweig Structural insights on the role of antibodies in HIV-1 vaccine and therapy Cell 156 2014 633 648
69. J.B. Whitney, A.L. Hill, S. Sanisetty, P. Penaloza-MacMaster, J. Liu, M. Shetty, L. Parenteau, C. Cabral, J. Shields, and S. Blackmore et al. Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys Nature 2014 10.1038/nature13594 Published online July 20, 2014
70. J.K. Wong, M. Hezareh, H.F. Günthard, D.V. Havlir, C.C. Ignacio, C.A. Spina, and D.D. Richman Recovery of replication-competent HIV despite prolonged suppression of plasma viremia Science 278 1997 1291 1295